首页> 外文期刊>Bone marrow transplantation >Allogeneic CD34+ -selected peripheral stem cell transplantation from parental donors in children with non-malignant diseases.
【24h】

Allogeneic CD34+ -selected peripheral stem cell transplantation from parental donors in children with non-malignant diseases.

机译:非恶性疾病儿童的同种异体CD34 +选择的外周血干细胞移植自父母供体。

获取原文
获取原文并翻译 | 示例
       

摘要

Allogeneic peripheral stem cell transplantation in six children with non-malignant hematologic or metabolic diseases which are eventually fatal was carried out with parental donors. Given three to five HLA mismatches, all grafts underwent CD34+ cell selection as graft-versus-host prophylaxis. The patients received median doses of 16.7 x 10(6) CD34+ cells/kg and 1.2 x 10(4) CD3+ cells/kg. All transplants engrafted. Neutrophils >0.5l were reached on day 11 (9-19) and platelets >50l on day 13 (10-25). Acute GVHD responding to steriods occured in three of six patients; it was restricted to the skin and overall did not exceed grade I. Two patients died of viral infections and four are alive with stable blood counts for 13, 15, 25 and 26 months. For children with non-malignant diseases which will eventually be fatal and which can be cured or ameliorated by allogeneic BMT, CD34+-selected stem cell transplants from mismatched or even haploidentical parents can be used if no other suitable donor is available. With high CD34+ cell doses and low CD3+ cell numbers, engraftment and avoidance of acute GVHD can be expected. Infections after transplantation remain the primary threat to survival.
机译:在六个非恶性血液病或新陈代谢疾病最终致死的儿童中进行了异体外周血干细胞移植,与父母的供体一起进行。考虑到三到五个HLA错配,所有移植物都经过CD34 +细胞选择,作为移植物抗宿主的预防措施。患者接受的中位剂量分别为16.7 x 10(6)CD34 +细胞/ kg和1.2 x 10(4)CD3 +细胞/ kg。所有移植物都被植入。在第11天(9-19)达到中性粒细胞> 0.5 / nl,在第13天(10-25)达到> 50 / nl血小板。六例患者中有三例发生了对偶发症的急性GVHD反应。它仅限于皮肤,总体不超过I级。2例患者死于病毒感染,其中4例存活,血液计数稳定在13、15、25和26个月。对于患有非恶性疾病的儿童,这些儿童最终将是致命的,并且可以通过同种异体BMT治愈或改善,如果没有其他合适的供体,则可以使用CD34 +选择的错配或什至单亲父母的干细胞移植。在高CD34 +细胞剂量和低CD3 +细胞数量的情况下,可以预期植入和避免急性GVHD。移植后的感染仍然是生存的主要威胁。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号